8 FDA label and trial tables · Checked
Zepbound label
In the Zepbound label, 6% to 8% on Zepbound (by dose) had shot-site reactions, like redness, itching, or bruising. On placebo, 2% did.
Each dot is 1 in 100 people.
Reported it Rest of a dose range Did not report it
Filled dots show the low end of a range. Dots are rounded. The exact number is above each grid.
EgriftaFDA-approved product
Row in the source: Reactions where the shot was given
SaxendaFDA-approved product
Row in the source: Reactions where the shot was given
SaxendaFDA-approved product
Row in the source: Pain where the shot was given
TymlosFDA-approved product
Row in the source: Redness where the shot was given
TymlosFDA-approved product
Row in the source: Swelling where the shot was given
TymlosFDA-approved product
Row in the source: Pain where the shot was given
VyleesiFDA-approved product
Row in the source: Reactions where the shot was given
ZepboundFDA-approved product
Row in the source: Shot-site reactions, like redness, itching, or bruising
CagrilintideNo FDA-approved product
Row in the source: Redness where the shot was given
CagrilintideNo FDA-approved product
Row in the source: Reactions where the shot was given
CagrilintideNo FDA-approved product
Row in the source: Itching where the shot was given
CagrilintideNo FDA-approved product
Row in the source: Rash where the shot was given
These lines are copied from our side effect pages, word for word.
In the first month of the women's trial, shot sites were checked one hour after each shot. Redness was seen in 58% of women on Tymlos and 28% on placebo. Swelling was seen in 11% and 3%, and pain in 10% and 7%.
The warnings section gives a higher count of shot-site problems than the table: 25% of people on Egrifta and 14% on placebo.
In the Mounjaro diabetes trials, allergic reactions were reported by 3.2% on Mounjaro and 1.7% on placebo. Some were severe, such as hives and eczema. Shot-site reactions were reported by 3.2% on Mounjaro and 0.4% on placebo.
Some people make antibodies to tirzepatide. In the Zepbound weight trials, shot-site reactions were reported by 11.3% of people on Zepbound who made these antibodies and 1% of those who did not.
From Mounjaro prescribing information on DailyMed and Zepbound prescribing information on DailyMed .
Each bar is one set of trials. The dots on this page come only from the time inside each bar.
Stated length Range in the source Some people only
Egrifta, adults with HIV26 weeks
Saxenda, adults32 to 56 weeks, some up to about 3 years
Saxenda, teens56 weeks
Tymlos, men12 months
Vyleesi, women24 weeks
Zepbound, adultsUp to 72 weeks
Cagrilintide, phase 226 weeks of treatment, side effects counted to week 32
Trials can miss rare harms and harms that take years to appear.
Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.
We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row still shows its own words from the source.
The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.
You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.